Skip to content

Study · Not a test of the peptide alone · 2023

4 results

Targeted heart repair by Tβ4-loaded cardiac-resident macrophage-derived extracellular vesicles modified with monocyte membranes.

Chen P, Pan Y, Ning X, Shi X, Zhong J, Fan X, Li W, Teng Y, Liu X, Yu B, Yang Y, Li H, Ou C

Acta biomaterialia18 Aug 2023Cited by 38 (Europe PMC)

PMID37597679 (opens in a new tab)DOI10.1016/j.actbio.2023.08.022 (opens in a new tab)PepBankPUB-37597679
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In mice with myocardial infarction, MmEVs and Tβ4-MmEVs reduced myocardial fibrosis compared with the control group.

    In plain wordsIn mice after a heart attack, vesicle treatments, one loaded with Tβ4, reduced heart tissue fibrosis compared with control.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseMyocardial fibrosis
    Study

    mousen: not reported in source

    Myocardial infarction (MI)
    Comparator
    Control
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Animal experiments suggested that MI mice treated with MmEVs and Tβ4-MmEVs exhibited reduced myocardial fibrosis and increased vascular density compared to the control group.
    1 context sentence
    Summary · context
    Additionally, to fully exploit the potential clinical application of MmEVs and achieve a better curative effect, thymosin β4 (Tβ4) was loaded into the nanoparticles, resulting in Tβ4-MmEVs.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In mice with myocardial infarction, MmEVs and Tβ4-MmEVs increased vascular density compared with the control group.

    In plain wordsIn mice after a heart attack, vesicle treatments, one loaded with Tβ4, increased blood vessel density compared with control.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseVascular density
    Study

    mousen: not reported in source

    Myocardial infarction (MI)
    Comparator
    Control
    Outcome group
    Angiogenesis · Cardiovascular

    Source sentences

    Summary
    Animal experiments suggested that MI mice treated with MmEVs and Tβ4-MmEVs exhibited reduced myocardial fibrosis and increased vascular density compared to the control group.
    1 context sentence
    Summary · context
    Additionally, to fully exploit the potential clinical application of MmEVs and achieve a better curative effect, thymosin β4 (Tβ4) was loaded into the nanoparticles, resulting in Tβ4-MmEVs.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome

    In cultured cardiomyocytes, both MmEVs and Tβ4-loaded MmEVs (Tβ4-MmEVs) promoted proliferation.

    In plain wordsIn cells, vesicles with or without Tβ4 loaded in them promoted heart muscle cell growth. The effect is for the vesicle product.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCardiomyocyte proliferation
    Study

    n: not reported in source

    Cardiomyocytes in vitro
    Comparator
    Control
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    In vitro experiments indicated that both the MmEVs and Tβ4-MmEVs promoted cardiomyocyte proliferation and endothelial cell migration.
    1 context sentence
    Summary · context
    Additionally, to fully exploit the potential clinical application of MmEVs and achieve a better curative effect, thymosin β4 (Tβ4) was loaded into the nanoparticles, resulting in Tβ4-MmEVs.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome

    In cultured endothelial cells, both MmEVs and Tβ4-MmEVs promoted cell migration.

    In plain wordsIn cells, vesicles with or without Tβ4 loaded in them promoted the movement of blood vessel lining cells. The effect belongs to the vesicle product.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseEndothelial cell migration
    Study

    n: not reported in source

    Endothelial cells in vitro
    Comparator
    Control
    Outcome group
    Angiogenesis · Cardiovascular

    Source sentences

    Summary
    In vitro experiments indicated that both the MmEVs and Tβ4-MmEVs promoted cardiomyocyte proliferation and endothelial cell migration.
    1 context sentence
    Summary · context
    Additionally, to fully exploit the potential clinical application of MmEVs and achieve a better curative effect, thymosin β4 (Tβ4) was loaded into the nanoparticles, resulting in Tβ4-MmEVs.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.